Pancreatic Cancer Screening in a Population at High Risk

Study acronym: ScrePan
StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Jun 30, 2026 → Nov 30, 2026
See other at-risk trials from Masaryk Memorial Cancer Institute

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jun 30, 2026 to Nov 30, 2026
    • Eligibility criteria expanded, about 16 words
    • Publications: details revised at 11 of 11 entries
  2. Primary completion date: Dec 31, 2025 to Jun 30, 2026v5
  3. Primary completion date: Jan 6, 2025 to Dec 31, 2025v4
  4. Secondary endpoints: details revised at 1 of 3 entriesv3
  5. Primary endpoint revisedv2
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pancreatic cancer is one of the diseases with the worst prognosis, which is mainly due to the initial asymptomatic prognosis. Unfortunately, the incidence of this disease in the Czech Republic is still increasing. In a certain proportion of patients, it is possible to predict the disease, e.g. due to family burdens. Regular follow-up of such individuals is the subject of the SCREPAN study: "Pancreatic Cancer Screening in High-Risk Persons".
Trial Details
NCT Number NCT06330441
Lead Sponsor Masaryk Memorial Cancer Institute
Collaborators: Masaryk University
Conditions
(from sponsor)		 Pancreatic Ductal Adenocarcinoma, Hereditary Diseases, Pancreatitis, Chronic
Related terms Genetic Diseases, Inborn, Pancreatitis, Chronic
Enrollment 700 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov